This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
CERE Overzicht aandelen
A clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Cerevel Therapeutics Holdings, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$44.96 |
| 52 Week Hoogtepunt | US$44.99 |
| 52 Week Laag | US$19.59 |
| Bèta | 1.41 |
| 11 maand verandering | 9.77% |
| 3 maanden verandering | 5.74% |
| 1 Jaar Verandering | 100.09% |
| 33 jaar verandering | 76.11% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 277.82% |
Recent nieuws en updates
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Rendement voor aandeelhouders
| CERE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.8% | -0.5% | 0.4% |
| 1Y | 100.1% | 18.3% | 32.6% |
Rendement versus industrie: CERE exceeded the US Biotechs industry which returned 15.5% over the past year.
Rendement versus markt: CERE exceeded the US Market which returned 16.6% over the past year.
Prijsvolatiliteit
| CERE volatility | |
|---|---|
| CERE Average Weekly Movement | 2.8% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: CERE has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: CERE's weekly volatility (3%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2018 | 355 | Ron Renaud | www.cerevel.com |
Cerevel Therapeutics Holdings, Inc. Samenvatting
| CERE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$8.19b |
| Inkomsten(TTM) | -US$460.47m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-17.8x
Koers/WinstverhoudingIs CERE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CERE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$460.47m |
| Inkomsten | -US$460.47m |
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.53 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 80.1% |
Hoe presteerde CERE op de lange termijn?
Bekijk historische prestaties en vergelijking